HIF-1: An Oxygen Response System with Special Relevance to the Kidney

Journal of the American Society of Nephrology

Volumn 14, Issue 11, 2003, Pages 2712-2722

  Maxwell, Patrick ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; ANTIBODY LABELING; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; ERYTHROPOIETIN GENE; GENE; GENE EXPRESSION; GENE INACTIVATION; GLUCOSE UTILIZATION; HUMAN; HYDROXYLATION; HYPOXIA INDUCIBLE FACTOR 1 GENE; OXYGEN CONSUMPTION; OXYGENATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TISSUE CULTURE; VON HIPPEL LINDAU DISEASE;

EID: 0142182781     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000092792.97122.E0     Document Type: Review

References (104)

1. 2 tension. Proc Natl Acad Sci U S A 92: 5510-5514, 1995
2. Schurek HJ, Jost U, Baumgartl H, Bertram H, Heckmann U: Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Physiol 259: F910-F915, 1990
3. Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: A new perspective. Kidney Int 26: 375-383, 1984
4. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U, Maher ER, Grone HJ, Eckardt KU: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res 61: 5215-5222, 2001
5. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999
6. Kaelin WG, Maher ER: The VHL tumour-suppressor gene paradigm. Trends Genet 14: 423-426, 1998
7. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001
8. 2 sensing. Science 292: 464-468, 2001
9. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science 292: 858-861, 2002
10. Schofield CJ, Zhang Z: Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 9: 722-731, 1999
11. Aravind L, Koonin EV: The DNA-repair protein A1kB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol 2: RESEARCH0007, 2001
12. Trewick SC, Henshaw TF, Hausinger RP, Lindahl T, Sedgwick B: Oxidative demethylation by Escherichia coli A1kB directly reverts DNA base damage. Nature 419: 174-178, 2002
13. Falnes PO, Johansen RF, Seeberg E: A1kB-mediated oxidative demethylation reverses DNA damage in Escherichia coli. Nature 419: 178-182, 2002
14. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ, Schofield CJ: Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J Biol Chem 278: 1802-1806, 2003
15. Lee C, Kim SJ, Jeong DG, Lee SM, Ryu SE: Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J Biol Chem 278: 7558-7563, 2003
16. Dann CE 3rd, Bruick RK, Deisenhofer J: Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci U S A 99: 15351-15356, 2002
17. Berk L, Burchenal JH, Castle WB: Erythropoietic effect of cobalt in patients with or without anemia. N Engl J Med 754-761, 1949
18. Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ: Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet 359: 407-408, 2002
19. Ren X, Dorrington KL, Maxwell PH, Robbins PA: Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J Appl Physiol 89: 680-686, 2000
20. Wang GL, Semenza GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 82: 3610-3615, 1993
21. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM: An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 93: 12969-12973, 1996
22. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ: Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 99: 5367-5372, 2002
23. Mahon PC, Hirota K, Semenza GL: FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686, 2001
24. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471, 2002
25. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ: Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 267: 571-575, 2002
26. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001
27. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12: 149-162, 1998
28. Ryan HE, Lo J, Johnson RS: HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998
29. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL: The hypoxia responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998
30. Peng J, Zhang L, Drysdale L, Fong GH: The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc Natl Acad Sci U S A 97: 8386-8391, 2000
31. Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997
32. Wiesener MS, Turley H, Allen WE, William C, Eckardt K-U, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH: Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1α. Blood 92: 2260-2268, 1998
33. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze C, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt K-U: Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J 17: 271-273, 2003
34. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU: Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002
35. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, Fujii-Kuriyama Y: HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22: 1134-1146, 2003
36. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M: Multiple splice variants of the human HIF-3α locus are targets of the VHL E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040, 2003
37. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L: Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001
38. Masson N, Wiliam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 21: 5197-5206, 2001
39. Bruick RK, McKnight SL: A conserved family of prolyl-4-Hydroxylases that modify HIF. Science 294: 1337-1340, 2001
40. Taylor MS: Characterization and comparative analysis of the EGLN gene family. Gene 275: 125-132, 2001
41. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, Kaelin WG Jr: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99: 13459-13464, 2002
42. Oehme F, Ellinghaus P, Kolkhof P, Smith T, Ramakrishnan S, Hutter J, Schramm M, Flamme I: Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 296: 343, 2002
43. Berra E, Richard DE, Gothie E, Pouyssegur J: HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett 491: 85-90, 2001
44. Cioffi CL, Liu XQ, Kosinski PA, Garay M, Bowen BR: Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun 297: 947-953, 2003
45. Wax SD, Rosenfield CL, Taubman MB: Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J Biol Chem 269: 13041-13047, 1994
46. Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB: Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 80: 421-426, 2002
47. Richard DE, Berra E, Gothie E, Roux D, Pouysségur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631-32637, 1999
48. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW: Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111: 709-720, 2002
49. Lavista-Llanos S, Centanin L, Irisarri M, Russo DM, Gleadle JM, Bocca SN, Muzzopappa M, Ratcliffe PJ, Wappner P: Control of the hypoxic response in Drosophila melanogaster by the basic helix-loop-helix PAS protein similar. Mol Cell Biol 22: 6842-6853, 2002
50. Vaux EC, Wood SM, Cockman ME, Nicholls LG, Yeates KM, Pugh CW, Maxwell PH, Ratcliffe PJ: Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor. J Biol Chem 276: 12, 2001.
51. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC: Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3: 75-88, 2003
52. Haase VH, Glickman JN, Socolovsky M, Jaenisch, R: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 98: 1583-1588, 2001
53. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS: HIF-1α is essential for myeloid cell-mediated inflammation. Cell 3: 645-657, 2003
54. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH: Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000
55. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97: 10430-10435, 2000
56. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, Jones EY: Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417: 975-978, 2002
57. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP: Structure of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science 296: 1886-1889, 2002
58. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G: The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1α transcriptional activity. EMBO J 22: 1857-1867, 2003
59. Maxwell PH, Pugh CW, Ratcliffe PJ: Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci U S A 90: 2423-2427, 1993
60. Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell PH, Koch CJ, Ratcliffe PJ, Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998
61. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS: Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23: 359-369, 2003
62. 2 tension. Am J Physiol 271: C1172-C1180, 1996
63. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M: Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 15: 1312-1314, 2001
64. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 149-162, 1997
65. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL: Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res 58: 5280-5284, 1998
66. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001
67. Chan DA, Sutphin PD, Denko NC, Giaccia AJ: Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 277: 40112-40117, 2002
68. 2 distribution in the living tissue. Kidney Int 51: 372-380, 1997
69. Vanderkooi JM, Erecinska M, Silver IA: Oxygen in mammalian tissue: Methods of measurement and affinities of various reactions. Am J Physiol 260: C1131-C1150, 1991
70. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999
71. Talks K, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411-421, 2000
72. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D: HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453, 2001
73. Ivanov SV, Kuzmin I, Wei M-H, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 95: 12596-12601, 1998
74. Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: Hypoxia inducible expression of tumor associated carbonic anhydrases. Cancer Res 60: 7075-7083, 2000
75. Ivanov S, Liao S-Y, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-918, 2001
76. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH: HIF activation identifies early lesions in VHL kidneys. Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468, 2002
77. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403-407, 1997
78. Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS: Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev 15: 2865-2876, 2001
79. Compemolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P: Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702-710, 2002
80. Ebert BL, Bunn HF: Regulation of the erythropoietin gene. Blood 94: 1864-1877, 1999
81. Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE: Cell type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A 88: 8725-8729, 1991
82. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJP, Johnson MH, Ratcliffe PJ: Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44: 1149-1162, 1993
83. Madan A, Lin C, Hatch SL II, Curtin PT: Regulated basal, inducible, and tissue-specific human erythropoietin gene expression in transgenic mice requires multiple cis DNA sequences. Blood 85: 2735-2741, 1995
84. Klassen DK, Spivak JL: Hepatitis-related hepatic erythropoietin production. Am J Med 89: 684-686, 1990
85. Naughton BA, Kaplan SM, Brudowski AJ, Roy M, Gordon AS, Piliero SJ: Hepatic regeneration and erythropoietin production in the rat. Science 196: 301-302, 1977
86. Tan CC, Eckardt K-U, Ratcliffe PJ: Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Kidney Int 40: 69-76, 1991
87. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Reme CE: HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8: 718-724, 2002
88. Westenfelder C: Unexpected renal actions of erythropoietin. Exp Nephrol 10: 294-298, 2002
89. Lappin TR, Maxwell AP, Johnston PG: EPO's alter ego: Erythropoietin has multiple actions. Stem Cells 20: 485-492, 2002
90. Sakanaka M, Wen T-C, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95: 4635-4640, 1998
91. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE: Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: Correlation with hematocrit, renal erythropoietin mRNA and serum erythropoietin concentration. Blood 74: 645-651, 1989
92. Bachmann S, Le Hir M, Eckardt K-U: Co-localization of erythropoietin messenger RNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41: 335-341, 1993
93. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 39: 26-29, 1985
94. Edmunds ME, Devoy M, Tomson CRV, Krishna U, Clayworth A, Durrant STS, Feehally J, Walls J: Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular haemodialysis treatment. Br J Haematol 78: 275-277, 1991
95. Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ: Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med 19: 65-69, 2002
96. Kurtz A, Eckardt K-U: Erythropoietin production in chronic renal disease before and after transplantation. Contrib Nephrol 87: 15-25, 1990
97. Midtvedt K, Stokke ES, Hartmann A: Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 11: 2495-2497, 1996
98. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994
99. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826, 1995
100. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER: Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10: 1029-1038, 2001
101. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WGJ: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027, 2001
102. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246, 2002
103. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT: Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614-621, 2002
104. Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM: Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104: 2216-2221, 2001